Post-earnings recap
Reported
Thu, May 5, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
BioCryst Pharmaceuticals reported a wider-than-expected loss per share, leading to a 3.93% decline in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's near-term outlook. The market reaction reflects uncertainty regarding their financial health and future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.40 | N/A | -3.09% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced in the quarter. They emphasized their commitment to ongoing development efforts.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on advancing their pipeline despite the current financial results.